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Background: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban (versus 
warfarin) significantly reduced stroke or systemic embolism, death and major bleeding in 18,201 patients with atrial fibrillation (AF) and at least one 
additional risk factor after a median follow-up of 1.8 years. Using empirical data from ARISTOTLE, we assessed the effect of apixaban therapy versus 
warfarin on medical resource use during the trial.
methods: Dates of all hospitalizations, length of stay and dates of cardiac and non-cardiac procedures were obtained from ARISTOTLE case report 
forms. Hospitalizations were classified as cardiovascular or non-cardiovascular based on event, procedure and adverse event data. Hospitalization 
frequency was estimated using Bang-Tsiatis methods, and compared between treatment groups in the overall population, as well as in the U.S. and 
non-U.S. cohorts. Cumulative length of stay was also examined.
results: Overall, 26.5% (n=4,831) of patients were hospitalized an average of 1.5 times during the study, with patients in the apixaban group 
experiencing a significant reduction in all-cause hospitalization compared to those in the warfarin group (25.9% versus 27.2%; p=0.04). Most of this 
difference was attributable to cardiovascular hospitalizations (15.7% versus 16.9%, p=0.02). While the number of hospitalizations per patient was 
similar between treatment groups (.43 versus .46 at 2 years; p=0.13), cumulative length of stay was shorter with apixaban (mean=2.86 versus 2.95 
days; p=0.05). In the U.S. cohort (n=3,417), the number of hospitalizations per patient was lower with apixaban (mean=.41 versus .48 at 2 years; 
p=0.05), accompanied by a non-significant reduction in cumulative length of stay (mean=1.70 versus 1.94; p=.19).
conclusions: In ARISTOTLE, apixaban (versus warfarin) was associated with small but significant reductions in the likelihood of hospitalization in 
patients with AF. For every 1,000 patients treated with apixaban instead of warfarin, 13 patients avoided hospitalization an average of 1.5 times 
during the study.
